These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38951305)

  • 1. A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients.
    Heerma van Voss MR; Notohardjo J; van Dodewaard-de Jong J; Bloemendal HJ; Heine RT
    Cancer Chemother Pharmacol; 2024 Jun; ():. PubMed ID: 38951305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer.
    Fujita K; Yoshino E; Kawara K; Maeda K; Kusuhara H; Sugiyama Y; Yokoyama T; Kaneta T; Ishida H; Sasaki Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):793-801. PubMed ID: 26297058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof-of-concept study.
    Boosman RJ; de Rouw N; Huitema ADR; Burgers JA; Ter Heine R
    Br J Clin Pharmacol; 2023 Feb; 89(2):699-704. PubMed ID: 36053283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
    Gustafson DL; Long ME; Zirrolli JA; Duncan MW; Holden SN; Pierson AS; Eckhardt SG
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):159-66. PubMed ID: 12759775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer.
    Cho EK; Park JY; Lee KH; Song HS; Min YJ; Kim YH; Kang JH
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):9-16. PubMed ID: 24337589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
    Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.
    van der Heijden LT; Ribbers CA; Vermunt MAC; Pluim D; Acda M; Tibben M; Rosing H; Douma JAJ; Naipal K; Bergman AM; Beijnen JH; Huitema ADR; Opdam FL
    J Clin Pharmacol; 2024 Feb; 64(2):155-163. PubMed ID: 37789682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol.
    Yamamoto N; Tamura T; Kamiya Y; Sekine I; Kunitoh H; Saijo N
    J Clin Oncol; 2000 Jun; 18(11):2301-8. PubMed ID: 10829051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.
    Vermunt MAC; van Nuland M; van der Heijden LT; Rosing H; Beijnen JH; Bergman AM
    Cancer Chemother Pharmacol; 2022 Jun; 89(6):785-793. PubMed ID: 35467095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
    Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of systemic exposure to unbound docetaxel and neutropenia.
    Baker SD; Li J; ten Tije AJ; Figg WD; Graveland W; Verweij J; Sparreboom A
    Clin Pharmacol Ther; 2005 Jan; 77(1):43-53. PubMed ID: 15637530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.
    Vermunt MAC; van der Heijden LT; Hendrikx JJMA; Schinkel AH; de Weger VA; van der Putten E; van Triest B; Bergman AM; Beijnen JH
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):855-869. PubMed ID: 33744986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
    Engels FK; Mathot RA; Loos WJ; van Schaik RH; Verweij J
    Cancer Biol Ther; 2006 Jul; 5(7):833-9. PubMed ID: 16775418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
    Lappin G; Kuhnz W; Jochemsen R; Kneer J; Chaudhary A; Oosterhuis B; Drijfhout WJ; Rowland M; Garner RC
    Clin Pharmacol Ther; 2006 Sep; 80(3):203-15. PubMed ID: 16952487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
    Lewis LD; Miller AA; Rosner GL; Dowell JE; Valdivieso M; Relling MV; Egorin MJ; Bies RR; Hollis DR; Levine EG; Otterson GA; Millard F; Ratain MJ;
    Clin Cancer Res; 2007 Jun; 13(11):3302-11. PubMed ID: 17545536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors.
    Gonçalves A; Viret F; Ciccolini J; Genre D; Gravis G; Giovanini M; Camerlo J; Catalin J; Maraninchi D; Viens P
    Clin Cancer Res; 2003 Jan; 9(1):102-8. PubMed ID: 12538457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients.
    Wei J; Zhang Y; Li Z; Li X; Zhao C
    Ann Transl Med; 2022 Jun; 10(12):705. PubMed ID: 35845493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
    van Zuylen L; Sparreboom A; van der Gaast A; Nooter K; Eskens FA; Brouwer E; Bol CJ; de Vries R; Palmer PA; Verweij J
    Eur J Cancer; 2002 May; 38(8):1090-9. PubMed ID: 12008197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.